艾拉莫德治疗强直性脊柱炎的初步观察  

Preliminary observation on the treatment of ankylosing spondylitis with Iguratimod

作　　者：林玉萍 刘红[1,3] 高锦团 LIN Yu-ping;LIU Hong;GAO Jin-tuan(Second Affiliated Hospital of Fujian Medical University & Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou City,Fujian 362000,China)

机构地区：[1]福建医科大学附属第二医院,福建省泉州市362000 [2]福建医科大学附属泉州市第一医院,福建省泉州市362000 [3]湖南省张家界市人民医院,427000

出　　处：《临床合理用药杂志》2019年第14期9-13,共5页Chinese Journal of Clinical Rational Drug Use

基　　金：泉州市科技计划项目(No:2015Z55)

摘　　要：目的观察艾拉莫德治疗强直性脊柱炎的临床疗效及安全性。方法将确诊为强直性脊柱炎活动期患者48例,随机分为观察组和对照组,每组24例。观察组采用艾拉莫德治疗,对照组采用传统抗风湿药(DMARDs)方案即柳氮磺吡啶联合甲氨蝶呤治疗,疗程均为24周。分别对治疗前、治疗第2、4、8、12、24周进行整体评估,比较2组临床疗效。结果从第8周开始,2组达到ASAS 40差异有统计学意义(P <0. 05),且随着时间推移,观察组达到ASAS 40的比例逐渐增长。在24周时,2组达到ASAS20、ASAS部分缓解、ASAS 5/6的差异有统计学意义(P <0. 05)。2组在疼痛评分、总体评估、BASDAI、BASFI的差异有统计学意义(P <0. 05)。观察组发生不良反应共3例,均为轻度且在研究期间好转或痊愈。结论艾拉莫德在治疗活动期强直性脊柱炎患者中具有较好的疗效和良好的安全性。Objective To observe the clinical efficacy and safety of Iguratimod tablets in the treatment of ankylosing spondylitis. Methods 48 patients with ankylosing spondylitis were randomly divided into observation group and control group,24 cases in each group. The observation group was treated with Iguratimod tablets,while the control group was treated with traditional antirheumatic drugs ( DMARDs),namely sulfasalazine combined with methotrexate,for 24 weeks. The clinica effects of 2,4,8,12 and 24 weeks of treatment were compared between the two groups. Results From the 8th week,there was a significant difference in ASAS 40 between the two groups ( P < 0. 05),and with the passage of time,the proportion of ASAS 40 in the observation group increased gradually. At 24 weeks,there were significant differences in ASAS 20,partial remission and ASAS 5 /6 between the two groups ( P < 0. 05). There were significant differences in pain score,overall assessment,BASDAI and BASFI between the two groups ( P < 0. 05). There were 3 cases of adverse reactions in the observation group,all of which were mild and improved or recovered during the study period. Conclusion Iguratimod tablets have good efficacy and safety in the treatment of patients with active ankylosing spondylitis.

关 键 词：强直性脊柱炎 艾拉莫德 治疗 

分 类 号：R593.23[医药卫生—内科学]